NCT05881265View on ClinicalTrials.gov

Treatment of Chidamide and Venetoclax for Retinoic Acid and Arsenic Resistant Acute Promyelocytic Leukemia

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 15, 2023

Primary Completion Date

January 1, 2026

Study Completion Date

January 1, 2026

Conditions
APL
Interventions
DRUG

Chidamide+venetoclax

Chidamide 30mg BIW x 4 weeks; Venetoclax 100mg D1, 200mg D2 and 400mg D3-28

Trial Locations (5)

200025

RECRUITING

Jiong HU, Shanghai

Unknown

NOT_YET_RECRUITING

The Affiliated Huai An No 1 Perople's Hospital of NanJing University, Huai'an

NOT_YET_RECRUITING

The First Affiliated Hospital of Nanchang University, Nanchang

ACTIVE_NOT_RECRUITING

Zhaxin Hospital, Go Broad Health Care, Shanghai

RECRUITING

NanFang Hospital, Guangzhou

All Listed Sponsors
collaborator

Shanghai Clinical Research Center

UNKNOWN

lead

Shanghai Jiao Tong University School of Medicine

OTHER